ENZAVA Trademark

Trademark Overview

On Monday, February 15, 2010, a trademark application was filed for ENZAVA with the United States Patent and Trademark Office. The USPTO has given the ENZAVA trademark a serial number of 77935753. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 30, 2013. This trademark is owned by ImClone LLC. The ENZAVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations in the treatment of cancer; pharmaceutical preparations, namely, monoclonal antibody regulating angiogenesis
enzava

General Information

Serial Number77935753
Word MarkENZAVA
Filing DateMonday, February 15, 2010
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 30, 2013
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 6, 2010

Trademark Statements

Goods and ServicesPharmaceutical preparations in the treatment of cancer; pharmaceutical preparations, namely, monoclonal antibody regulating angiogenesis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 18, 2010
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameImClone LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNew York, NY 10016
Party NameImClone LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNew York, NY 10014

Trademark Events

Event DateEvent Description
Monday, September 30, 2013ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, September 30, 2013ABANDONMENT - NO USE STATEMENT FILED
Wednesday, January 23, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 22, 2013EXTENSION 5 GRANTED
Monday, January 14, 2013EXTENSION 5 FILED
Monday, January 14, 2013TEAS EXTENSION RECEIVED
Saturday, August 11, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 10, 2012EXTENSION 4 GRANTED
Tuesday, August 7, 2012EXTENSION 4 FILED
Tuesday, August 7, 2012TEAS EXTENSION RECEIVED
Saturday, January 28, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 27, 2012EXTENSION 3 GRANTED
Wednesday, January 25, 2012EXTENSION 3 FILED
Wednesday, January 25, 2012TEAS EXTENSION RECEIVED
Tuesday, January 24, 2012APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, January 24, 2012TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, August 23, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 22, 2011EXTENSION 2 GRANTED
Friday, August 12, 2011EXTENSION 2 FILED
Monday, August 22, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, August 12, 2011TEAS EXTENSION RECEIVED
Saturday, February 12, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 10, 2011EXTENSION 1 GRANTED
Thursday, February 10, 2011EXTENSION 1 FILED
Thursday, February 10, 2011TEAS EXTENSION RECEIVED
Tuesday, August 31, 2010NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 6, 2010OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 6, 2010PUBLISHED FOR OPPOSITION
Tuesday, June 1, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, June 1, 2010ASSIGNED TO LIE
Tuesday, May 18, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 18, 2010ASSIGNED TO EXAMINER
Thursday, February 18, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, February 18, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

enzava pharmaceutical preparations regulating angiogenesis antibody namely treatment cancer monoclonal